Methylxanthines modulate adenosine release from slices of cerebral cortex

Stone, T.W.; Hollins, Carolyn; Lloyd, H.G.E.

doi:10.1016/0006-8993(81)90374-7

Cited by 25 publications

(6 citation statements)

References 37 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, previous examination of the characteristics of ouabain-evoked purine release was performed on tissue from rats only (Hollins & Stone 1980b) and it is possible that the properties of cortex slices important for ouabain-evoked release differ in rats and mice. We have concluded elsewhere that purine release by ouabain is probably not due to a simple inhibition of (Na+, K+) ATPase (Hollins, Stone & Lloyd, 1980;Stone, Hollins & Lloyd, 1981;.…”

Section: Discussionmentioning

confidence: 83%

The Effects of Morphine and Methionine‐enkephalin on the Release of Purines From Cerebral Cortex Slices of Rats and Mice

Stone

1981

British J Pharmacology

Self Cite

View full text Add to dashboard Cite

1 Slices of cerebral cortex from Wistar rats, TO mice or C57 mice were preincubated with [3H]-adenosine, and labelled purines were subsequently released by electrical stimulation or by perfusing with ouabain, 100 pM. 2 Electrically-evoked purine release was substantially reduced when the Ca2+ concentration in the medium was lowered from 2.4 to 0.1 mM. In both rats and mice, the electrically-evoked release was increased by morphine and methionine-enkephalin (Met-enkephalin), 10 fM and in rats and TO mice by morphine 1 Mm, both drug effects being prevented by naloxone. 3 Purine release evoked by ouabain was also increased by morphine 1 and 10 pM, though not by Met-enkephalin, from slices of rat cortex. Ouabain-induced release from TO mice was reduced by morphine, and from C57 mice was unchanged. 4 The enhancement by morphine of electrically-evoked purine release may indicate that purines mediate some effects of morphine in the CNS.

show abstract

Section: Discussionmentioning

confidence: 83%

The Effects of Morphine and Methionine‐enkephalin on the Release of Purines From Cerebral Cortex Slices of Rats and Mice

Stone

1981

British J Pharmacology

Self Cite

View full text Add to dashboard Cite

show abstract

“…Furthermore, it has been demonstrated that en urane and sevo urane have the ability to activate adenosine A 1 receptors in an in-vitro culture of rat hippocampus [1]. Aminophylline is a nonselective antagonist of the adenosine receptor [17], and it can decrease the sedation effects of sevo urane [5,18], but not the anaesthesia induced by des urane [4]. Sevo urane is one of the most potent volatile anaesthetics that potentiates the effect of neuromuscular blocking agents [19].…”

Section: Discussionmentioning

confidence: 99%

Effects of Sevoflurane and Adenosine Receptor Antagonist on the Sugammadex-Induced Recovery from Rocuronium-Induced Neuromuscular Blockade: An Ex-vivo Study

Kim

Choi

Park

et al. 2020

Preprint

View full text Add to dashboard Cite

Background: Sevoflurane affects on the A1 receptor in the central nervous system (CNS) and potentiates the action of neuromuscular blocking agents. In the present study, we investigated whether sevoflurane (SEVO) has the ability to potentiate the neuromuscular blocking effect of rocuronium and if the specific antagonist of adenosine receptor (SLV320) can reverse this effect. Methods: Phrenic nerve–hemidiaphragm tissue specimens were obtained from forty Sprague-Dawley (SD) rats. The specimens were immersed in an organ bath filled with Krebs buffer and stimulated by a train-of-four (TOF) pattern using indirect supramaximal stimulation at 20 s intervals. The specimens were randomly allocated to control, 2-chloroadenosine (CADO), SEVO, or SLV320+SEVO groups. In the CADO and SLV320+SEVO groups, CADO and SLV320 were added to the organ bath from the start to a concentration of 10 μM and 10 nM, respectively. We then proceeded with rocuronium-induced blockade of >95% depression of the first twitch tension of TOF (T1) and TOF ratio (TOFR). In the SEVO and SLV320+SEVO groups, SEVO was added to the Krebs buffer solution to concentration of 400 - 500 μM for 10 min. Sugammadex-induced T1 and TOFR recovery was monitored for 30 min until >95% of T1 and >0.9 of TOFR were confirmed, and the recovery pattern was compared by plotting these data. Results: There were no significant differences in the recovery pattern between the control and SEVO groups. However, there were significant differences between the SEVO and SLV320+SEVO groups. Conclusion: Sevoflurane potentiates of rocuronium-induced neuromuscular blocking effect and delays sugammadex-induced recovery from neuromuscular blockade.

show abstract

“…This effect is suggested to be mediated by an interaction of volatile anesthetics with ADO transport or a key enzyme in ADO metabolism. Aminophylline is a nonselective antagonist of the adenosine receptor [ 22 ] and can decrease the sedative effects of sevoflurane [ 23 , 24 ] but not desflurane-induced anesthesia [ 25 ]. Sevoflurane is known as one of the most potent volatile anesthetics for potentiating the action of the neuromuscular blocking agents [ 26 ].…”

Section: Discussionmentioning

confidence: 99%

Effects of adenosine receptor agonist on the rocuroniuminduced neuromuscular block and sugammadex-induced recovery

Kim

Lee

Choi

et al. 2018

Korean J Anesthesiol

View full text Add to dashboard Cite

BackgroundSeveral types of receptors are found at neuromuscular presynaptic membranes. Presynaptic inhibitory A1 and facilitatory A2A receptors mediate different modulatory functions on acetylcholine release. This study investigated whether adenosine A1 receptor agonist contributes to the first twitch tension (T1) of train-of-four (TOF) stimulation depression and TOF fade during rocuronium-induced neuromuscular blockade, and sugammadex-induced recovery.MethodsPhrenic nerve-diaphragm tissues were obtained from 30 adult Sprague-Dawley rats. Each tissue specimen was randomly allocated to either control group or 2-chloroadenosine (CADO, 10 μM) group. One hour of reaction time was allowed before initiating main experimental data collection. Loading and boost doses of rocuronium were sequentially administered until > 95% depression of the T1 was achieved. After confirming that there was no T1 twitch tension response, 15 min of resting time was allowed, after which sugammadex was administered. Recovery profiles (T1, TOF ratio [TOFR], and recovery index) were collected for 1 h and compared between groups.ResultsThere were statistically significant differences on amount of rocuronium (actually used during experiment), TOFR changes during concentration-response of rocuronium (P = 0.04), and recovery profiles (P < 0.01) of CADO group comparing with the control group. However, at the initial phase of this experiment, dose-response of rocuronium in each group demonstrated no statistically significant differences (P = 0.12).ConclusionsThe adenosine A1 receptor agonist (CADO) influenced the TOFR and the recovery profile. After activating adenosine receptor, sugammadex-induced recovery from rocuronium-induced neuromuscular block was delayed.

show abstract

Methylxanthines modulate adenosine release from slices of cerebral cortex

Cited by 25 publications

References 37 publications

The Effects of Morphine and Methionine‐enkephalin on the Release of Purines From Cerebral Cortex Slices of Rats and Mice

The Effects of Morphine and Methionine‐enkephalin on the Release of Purines From Cerebral Cortex Slices of Rats and Mice

Effects of Sevoflurane and Adenosine Receptor Antagonist on the Sugammadex-Induced Recovery from Rocuronium-Induced Neuromuscular Blockade: An Ex-vivo Study

Effects of adenosine receptor agonist on the rocuroniuminduced neuromuscular block and sugammadex-induced recovery

Contact Info

Product

Resources

About